The Filing Desk

aTYR Pharma

ATYR · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ATYR · Last close · November 19, 2026
$3.69
Value aTYR Pharma yourself

aTYR Pharma's revenue fell 19.1% to $0 million in fiscal 2025. Its operating margin was −40,856.3%, down from −28,899.6% a year earlier. Free cash flow was −$62 million. The diluted share count rose 25.2%.

ATYR PHARMA, INC. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001339970-26-000008 Updated
Revenue
$0M
19.1%
Operating margin
−40,856.3%
11956.8 pts
Net income
−$74M
 
Free cash flow
−$62M
 
Return on equity
−107.8%
28.1 pts
Market cap
$9M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What aTYR Pharma does

aTYR Pharma is a clinical stage biotechnology company. It has no products on the market. It is developing new drugs for fibrosis (scarring) and inflammation, based on its research into tRNA synthetases, ancient proteins found in every human cell.

Its lead drug candidate is efzofitimod, a biologic given by infusion for interstitial lung disease, a group of disorders that can inflame and scar the lungs. The company tested it in a large Phase 3 trial in pulmonary sarcoidosis. The trial did not meet its main goal, which was a lower daily steroid dose at week 48, though the company points to gains on some other measures. It plans to meet the FDA to decide what comes next. A smaller Phase 2 trial in lung disease linked to systemic sclerosis (scleroderma) is also under way.

With no product sales, aTYR depends on its collaboration with Kyorin Pharmaceutical, which holds the rights to efzofitimod in Japan, and on outside funding. It relies on contract manufacturers and research organizations to make the drug and run its trials. It had 58 employees at the end of 2025, most of them in research, clinical and regulatory roles.

Its biggest risks, as it describes them

  • Clinical trials may fail or be delayed, as the main goal of its Phase 3 sarcoidosis trial was missed.
  • It may never win regulatory approval for efzofitimod or other candidates, or sell them successfully.
  • It relies on outside companies to make its drug candidates and run its clinical trials.
  • It may be unable to protect its patents, or may be accused of infringing the patents of others.
  • Its collaborations, such as the Kyorin agreement in Japan, may not succeed.
From aTYR Pharma's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

aTYR Pharma lost money in fiscal 2025: a net loss of $74 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments10866987279
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—−859.3x−319.3x−495.7x−825.8x
Current ratio18.9x5.8x6.3x5.5x5.3x
Quick ratio18.9x5.8x6.3x5.5x5.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project aTYR Pharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What aTYR Pharma says to expect

  • Cash runway: current cash positionBased on its current cash and operating expense forecast and plans, the Company anticipates that this cash position will be sufficient to fund the Company’s current operations into late 2028.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $50,000 of aTYR Pharma shares on the open market, and 3 insiders sold $6,293.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
May 27, 2026Paul SchimmelDirectorBought100,000$0.50$50,000Form 4
Feb 4, 2026Sanjay ShuklaPresident and CEO, DirectorSold3,745$0.98$3,670Form 4
Feb 4, 2026Jill Marie BroadfootChief Financial OfficerSold1,558$0.98$1,527Form 4
Feb 4, 2026Nancy DenyesGeneral CounselSold1,118$0.98$1,096Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−10,701.7%−29,473.4%−32,683.9%
Altman Z''−7.85−15.37−19.52
Accruals ratio−15.9%4.7%−12.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assets———
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailFailPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put aTYR Pharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
aTYR PharmaFY25−19.1%−40,856.3%−32,664.7%———
BioRestorative TherapiesFY25−10.3%−4,350.1%−3,031.7%———Compare
Connect BiopharmaFY25−99.8%−90,740.6%−80,687.5%——1Compare
Cardiff OncologyFY25−13.2%−8,256.3%−6,402.5%——2Compare
PMGC HoldingsFY25——−1,080.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue———010010000
Revenue growth————2,377.5%−100.0%—−96.6%−33.4%−19.1%
Gross profit——————————
Research and development43302014172343425460
Operating income−58−47−33−23−16−34−46−55−68−78
Net income−58−48−34−16−16−34−45−50−64−74
Diluted EPS (US$)−2.44−26.13−16.11−7.03−1.77−1.77−1.60−0.94−0.86−0.80
Diluted shares (millions)2422391928547493
Cash flow
Cash from operations−53−42−31−20−15−33−42−33−69−62
Capital expenditure1110002400
Free cash flow−53−44−32−20−16−33−44−37−69−62
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation5732222335
Balance sheet at fiscal year end
Cash and short-term investments728550313210866987279
Debt incl. finance leases102016———————
Total assets8089533639116961219793
Total liabilities182519157624302726
Shareholders' equity636434213210972917068
Margins and ratios
Gross margin——————————
Operating margin———−5,445.0%−152.2%—−446.8%−15,557.8%−28,899.6%−40,856.3%
Net margin———−3,844.6%−155.2%—−436.5%−14,274.5%−27,243.8%−39,009.5%
Free cash flow margin———−4,761.1%−148.3%—−419.1%−10,605.1%−29,440.0%−32,664.7%
Rule of 40 (growth + FCF margin)————2,229.2%——−10,701.7%−29,473.4%−32,683.9%
Return on capital−368.4%—————————
Return on equity−65.1%−75.9%−70.5%−59.2%−61.4%−47.9%−50.2%−62.2%−79.7%−107.8%
Return on assets−55.0%−56.8%−48.6%−36.5%−43.3%−43.8%−42.9%−46.6%−58.9%−78.1%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: aTYR Pharma's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with aTYR Pharma.